Can bariatric surgery cure metabolic syndrome?;Cirurgia bariátrica cura síndrome metabólica?

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 1, 2007, Pages 79-85

  De Carvalho, Perseu Seixas ^a,c   Moreira, Cora Lavigne De C B ^a   Barelli, Melina Da Costa ^a   De Oliveira, Flávia Heringer ^a   Guzzo, Mariana Furieri ^a   Miguel, Gustavo P Soares ^b   Zandonade, Eliana ^b  

^a Serviço de Endocrinologia do Hospital   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c NONE   (Brazil)

Author keywords

Cardiovascular risk factors; Dyslipidemia; Gastric bypass; Hypertension; Obesity; Type 2 diabetes mellitus; Weight loss

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; BODY MASS; CLASSIFICATION; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METHODOLOGY; MORBID OBESITY; PHYSIOLOGY; POSTOPERATIVE CARE; PREOPERATIVE CARE; STOMACH BYPASS; TIME; TREATMENT OUTCOME; WAIST HIP RATIO;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; FEMALE; GASTRIC BYPASS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY, MORBID; POSTOPERATIVE CARE; PREOPERATIVE CARE; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 34247145546     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302007000100013     Document Type: Article

References (46)

1. Reaven GM. Insulin resistance and its consequences. In: LeRoith D, Olefsky JM, Taylor SI, eds. Diabetes mellitus: A fundamental and clinical text. Bethesda: Lippincott Williams & Wilkins, 2004. pp. 899-915.
2. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome (IRAS). Circulation 2000;102 (1):42-7.
3. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51(2):455-61.
4. Ferranini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997;100:1166-73.
5. Lakka HM, Laaksonen DE, Lakka TA, Niskanem LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
6. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575-81.
7. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541-5.
8. Gang H, Qiao Q, Tuomilehto J, Balkau B, Borchjohnsen K, Pyorala K;for DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76.
9. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, et al;for the 4S Group and AFCAPS/TextCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian simvastatin survival study (4S) and the air force/Texas coronary atherosclerosis prevention study (AFCAPS/TextCAPS). Am J Cardiol 2004;93:136-41.
10. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR. Effects of obesity surgery on the metabolic syndrome. Arch Surg 2004;139(10):1088-92.
11. Case CC, Jones PH, Nelson K, O'Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002;4:407-14.
12. NIH Conference: gastrointestinal surgery for severe obesity. Ann Intern Med 1991;115:959-61.
13. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA 2002;288:2793-6.
14. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001;120:669-81.
15. Jones Jr KB. Experience with the Roux-en-Y gastric by-pass, and commentary on current trends. Obes Surg 2000;10: 183-5.
16. Brolin RE, Kenler HA, Wilson AC, Kuo PT, Cody RP. Serum lipids after gastric bypass surgery for morbid obesity. Int J Obes Relat Metab Disord 1990;14:939-50.
17. Wolf AM, Beisegel U, Kortner B, Kuhlman HW. Does gastric restriction surgery reduce the risks of metabolic diseases? Obes Surg 1998;8:9-13.
18. Brolin RE. Update. NIH Consensus Conference. Gastrointestinal surgery for severe obesity. Nutrition 1996;12:403-4.
19. Grace DM. Gastric reduction procedures for treating severe obesity. Am J Clin Nutr 1992;55:S556-9.
20. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middled-aged adults - The ARIC Study. Obes Res 2000;8(4):279-86.
21. Pratley R, Wilson C, Bogardus C. Relation of white blood cell count to obesity and insulin resistance: effect of race and gender. Obes Res 1995;3:563-71.
22. Yarnell JWG, Baker IA, Sweetnam PA. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell collaborative heart disease studies. Circulation 1999;83:836-44.
23. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk Communities Study): a cohort study. Lancet 1999;353(9165):1649-52.
24. WHO. Obesity preventing and managing the global epidemic, 1998.
25. Kolanowski J. Surgical treatment for morbid obesity. Br Med Bull 1977;53:433-4.
26. McTigue KM, Harris R, Hemphill B, Lux L, Sutton S, Bunton AJ, et al. Screening and interventions for obesity in adults: summary of the evidence for us prevention services task force. Ann Intern Med 2003;139(11):933-49.
27. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, et al. Who would have thought? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg 1995;222:339-52.
28. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238 (4):467-84.
29. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237(6):751-6.
30. Wittgrove AC, Clark GW. Laparoscopic gastric bypass Rouxen-Y-500 patients: technique and results, with 3-60 months follow-up. Obes Surg 2000;10(3):233-9.
31. Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232(4):515-29.
32. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Human plasma ghrelin levels after diet-induced weight loss and gastric bypass surgery. N Engl J Med 2002;346(21):1623-30.
33. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide-1 on glycemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
34. Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism in human obesity. Am J Physiol 1994;266:E600.
35. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hiperinsulinemia on VLDL triglyceride and VLDL ApoB production in normal weight and obese individuals. Diabetes 1993;42(6):833-42.
36. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40(4):454-62.
37. Swenson TL. The role of the cholesteryl ester transfer protein in lipoprotein metabolism. Diabetes Metab Rev 1991;7(3):139-53.
38. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317(6):350-7.
39. Swislocki AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989;2(6 pt. 1):419-23.
40. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996;9(8):746-52.
41. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-82.
42. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287(11):1420-6.
43. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
44. Nakanishi N, Sato M, Shirai K, Nakajima K, Murakami S, Takatorige T, et al. Association between white blood cell count and features of the metabolic syndrome in Japanese male office workers. Ind Health 2002;40(3):273-7.
45. Alvarez-Cordero R. Final reflexions: wellness after obesity surgery. World J Surg 1998;22:1018-21.
46. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351(26):2683-93.